Reading ALUR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALUR free→Reading ALUR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALUR free→QuarterlyIQ Insights · ALUR
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Changes in Registrant’s Certifying Accountant. Dismissal of Independent Registered Public Accounting Firm Deloitte & Touche LLP (“Deloitte”) has served as the independent registered public accounting firm for Allurion Technologies, Inc. (the “Company”) since 2016. On May 22, 2026 (the “Effective Date”), Deloitte was dismissed as our independent registered public accounting firm. The decision to dismiss Deloitte was approved by the Audit Committee of the Board of Directors (the “Audit Committe…
Other Events. On March 12, 2026, the Company issued a press release in connection with the delisting notice of its Common Stock and Warrants from the NYSE and its appeal of the delisting determination described above. As discussed in the press release, the Company's recent FDA approval of the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, catalyzed a detailed plan to regain compliance with NYSE listing standards or to relist its securities on the NYSE American, strengt…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 6, 2026, the New York Stock Exchange (“NYSE”) notified Allurion Technologies, Inc. (“Allurion” or the “Company”) that it has determined to commence proceedings to delist the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and warrants to purchase 0.056818 shares of Common Stock, with an exercise price of $202.50 per share of Common Stock (the “Warrants”), as…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On March 2, 2026, Allurion Technologies, Inc., a Delaware corporation (the “Company”) announced that it received a letter (the “Delisting Notice”) from the staff of the New York Stock Exchange (the “Exchange” or “NYSE”) indicating that the Company does not meet certain of the Exchange’s continued listing standards as set forth in Section 802.01B of the NYSE Listed Company Manual that require li…
Unregistered Sales of Equity Securities. The information set forth in
Material Modification to Rights of Security Holders. The information set forth in
Entry into a Material Definitive Agreement. On February 24, 2026, Allurion Technologies, Inc. (the “Company”) entered into a warrant exercise inducement offer letter (the “Inducement Letter”) with certain holders (the “Exercising Holders”) of certain of the Company’s: (i) warrants issued in January 2025 to purchase shares of common stock, par value $0.0001 per share (“Common Stock”), with an exercise price of $6.00 per share (the “January 2025 Warrants”); (ii) warrants issued in February 2025…
and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this item of this report. Forward-Looking Statements…
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set…
Entry into a Material Definitive Agreement Securities Purchase Agreement On November 11, 2025, Allurion Technologies, Inc. (the “Company” or “Allurion”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell 2,994,012 shares (the “Private Placement Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and acco…
by reference, the Private Placement Securities and the Series B Preferred Stock (including the Common Stock issuable upon exercise of the Private Placement Warrants or conversion of the Series B Preferred Stock) (collectively, the “Private Securities”) were issued in reliance upon the exemption from registration pursuant to Section 4(a)(2) under the Securities Act and Regulation D under the Securities Act, and corresponding provisions of state securities or “blue sky” laws. The sale of the Pr…
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such fil…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On September 30, 2025, Milena Alberti-Perez, a Class III member of the board of directors (the “Board”) of Allurion Technologies, Inc. (the “Company”), notified the Company of her resignation from the Board and her role as the chairperson of the Audit Committee of the Board (the “Audit Committee”), effective September 30, 2025. Ms. Alberti-Perez’s re…
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review On August 14, 2025, the Audit Committee of the Board of Directors (the “Audit Committee”) of Allurion Technologies, Inc. (the “Company”) concluded that certain of the Company’s previously issued financial statements, as described below, should no longer be relied upon due to errors identified in the accounting related to the fair value of the RIFA and the Notes (each as defined below),…
Results of Operations and Financial Condition. On August 13, 2025, Allurion Technologies, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2025. The full text of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. In connection with preparation of the Company’s unaudited quarterly financial statements for the quarter ended June 30, 2025, a potential mi…
Results of Operations and Financial Condition. On August 5, 2025, Allurion Technologies, Inc. (the “Company”) announced select preliminary unaudited financial results for the second quarter ended June 30, 2025. This information is preliminary and unaudited and reflects the Company’s estimated financials results for the second quarter 2025. The Company’s actual financial results for the second quarter ended June 30, 2025, have not yet been finalized by management or reviewed by the Company’s i…
Costs Associated with Exit or Disposal Activities. On August 5, 2025, the Company announced a strategic restructuring plan adopted by the Company’s board of directors on July 23, 2025 (the “Restructuring Plan”). In connection with the Restructuring Plan, the Company is focusing on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry, in combination with other cost-saving measures. The Restructuring Plan includes a reduction in force of approximately 70 employees,…
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set…
Unregistered sales of Equity Securities The information set forth under the heading "Amendment to Note Purchase Agreement" in
Entry into a Material Definitive Agreement. Amendment to Note Purchase Agreement As previously disclosed, on April 14, 2024, Allurion Technologies, Inc., a Delaware corporation (the “Company”), RTW Investments, LP (“RTW”), as agent for the purchasers (the “Purchasers”) party thereto from time to time (RTW in such capacity, the “Principal Purchaser”), and Acquiom Agency Services LLC, as collateral agent for the Purchasers and the Principal Purchaser, entered into a Note Purchase Agreement (the…
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set…
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'inexpensive' to 'None'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.